Table 2 Two way ANOVA analyses of all studied parameters in all groups regarding gender, Zn treatment, and gender versus ZnSO4 treatment.
Studied parameters | Zn-treatment | Gender | Zn-treatment/gender | |||
|---|---|---|---|---|---|---|
F | p | F | P | F | p | |
Total weight | 118.65 | Ë‚ 0.0001 | 746.18 | Ë‚ 0.0001 | 5.41 | 0.0002 |
Serum markers | ||||||
 Zn | 53.72 | ˂ 0.0001 | 380.63 | ˂ 0.0001 | 11.51 | ˂ 0.0001 |
 Leptin | 228.51 | ˂ 0.0001 | 2045.89 | ˂ 0.0001 | 45.45 | ˂ 0.0001 |
 Glucose level | 80.56 | ˂ 0.0001 | 0.00 | 0.9756 | 3.74 | 0.0034 |
Brain markers | ||||||
 Leptin receptor | 228.51 | ˂ 0.0001 | 2045.89 | ˂ 0.0001 | 45.45 | ˂ 0.0001 |
 PDNF | 1246.42 | ˂ 0.0001 | 465.32 | ˂ 0.0001 | 14.46 | ˂ 0.0001 |
 p-STAT3 | 283.27 | ˂ 0.0001 | 155.63 | ˂ 0.0001 | 4.87 | 0.0004 |
 AChE | 6.63 | ˂ 0.0001 | 61.75 | ˂ 0.0001 | 33.81 | ˂ 0.0001 |
Lipid profile | ||||||
 Total Lipids | 23.4 | ˂ 0.0001 | 365.91 | ˂ 0.0001 | 2.91 | 0.0158 |
 Cholesterol | 20.18 | ˂ 0.0001 | 147.03 | ˂ 0.0001 | 1.21 | 0.3072 |
 Triglycerides | 110.47 | ˂ 0.0001 | 128.92 | ˂ 0.0001 | 15.24 | ˂ 0.0001 |
Liver enzymes | ||||||
 SGOT | 34.78 | ˂ 0.0001 | 150.27 | ˂ 0.0001 | 15.22 | ˂ 0.0001 |
 SGPT | 134.15 | ˂ 0.0001 | 445.15 | ˂ 0.0001 | 37.49 | ˂ 0.0001 |
Kidney functions test | ||||||
 Urea | 16.3 | ˂ 0.0001 | 4.54 | 0.0350 | 0.51 | 0.7681 |
 Uric acid | 39.25 | ˂ 0.0001 | 9.38 | 0.0027 | 11.90 | ˂ 0.0001 |
 Creatinine | 2.02 | 0.0798 | 7.83 | 0.0059 | 1.55 | 0.1791 |
